Kelli Mills
Psychiatric/Mental Health · London, KYNPI 1235622390
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 262 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 17.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,813, 7.0 times the $259 reported in 2021. Among psychiatric/mental health clinicians in KY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 262 payments — averaging $19.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$884
- Otsuka America Pharmaceutical, Inc.$794
- Vanda Pharmaceuticals Inc.$566
- Johnson & Johnson$540
- Alkermes, Inc.$422
- E.r. Squibb & Sons, L.L.C.$247
- plus $2K from 13 others
What the payments were for
- Food & beverage$4,96999%
- Education$471%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 41 | $884 |
| Otsuka America Pharmaceutical, Inc. | 47 | $794 |
| Vanda Pharmaceuticals Inc. | 29 | $566 |
| Johnson & Johnson | 16 | $540 |
| Alkermes, Inc. | 34 | $422 |
| E.r. Squibb & Sons, L.L.C. | 8 | $247 |
| Lundbeck LLC | 16 | $243 |
| Axsome Therapeutics, Inc. | 11 | $223 |
| Ironshore Pharmaceuticals Inc. | 13 | $219 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 10 | $201 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $127 |
| Almatica Pharma LLC | 4 | $100 |
| Teva Pharmaceuticals USA, Inc. | 5 | $93 |
| Biogen | 4 | $87 |
| Supernus Pharmaceuticals, Inc. | 5 | $79 |
| Indivior Inc. | 2 | $73 |
| Idorsia Pharmaceuticals US Inc | 4 | $57 |
| Neurocrine Biosciences, Inc. | 3 | $44 |
| Avanir Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$247
- SPRAVATO$145
- REXULTI$125
- COBENFY$125
- ABILIFY MAINTENA$121
How this compares
$5,016 in reported general payments places this provider in the 90th percentile of 946 psychiatric/mental health providers in Kentucky.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 14 | $43,356 |
| CaplytaLumateperone Tosylate | 13 | $21,254 |
| RexultiBrexpiprazole | 12 | $17,299 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 77 | $7,438 |
| Citalopram HbrCitalopram Hydrobromide | 14 | $1,378 |
| Aripiprazole | 26 | $1,375 |
| Quetiapine Fumarate | 98 | $1,036 |
| Duloxetine Hcl | 50 | $709 |
| Fluoxetine Hcl | 84 | $698 |
| Buspirone Hcl | 59 | $519 |
| Amitriptyline Hcl | 42 | $321 |
| Clonazepam | 55 | $168 |
| Propranolol Hcl | 19 | $163 |
| Sertraline Hcl | 56 | $139 |
| Trazodone Hcl | 44 | $136 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $540 | $43,35614 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $201 | $21,25413 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $794 | $17,29912 claims |
| Almatica Pharma LLCSertraline Hcl | $100 | $13956 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 946 psychiatric/mental health providers in Kentucky.
Other psychiatric/mental health in London
- Tammy WhiteheadLondon$19K
- Jerry KunkelLondon$13K
- Theresa WattsAshland$645K
- Rachel ColeHopkinsville$503K
- Denise de AngelisLouisville$384K
- Jennifer SampangCrestview Hills$322K
- Jeremy FisherSouth Shore$197K
- Jessica EstesLewisport$175K
- Christopher MulloneyNancy$95K
- Davika MattoxMorehead$79K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.